Revisiting Type 2‐high and Type 2‐low airway inflammation in asthma: current knowledge and therapeutic implications

Citations Over TimeTop 1% of 2016 papers

Abstract

Asthma is a complex respiratory disorder characterized by marked heterogeneity in individual patient disease triggers and response to therapy. Several asthma phenotypes have now been identified, each defined by a unique interaction between genetic and environmental factors, including inflammatory, clinical and trigger-related phenotypes. Endotypes further describe the functional or pathophysiologic mechanisms underlying the patient's disease. type 2-driven asthma is an emerging nomenclature for a common subtype of asthma and is characterized by the release of signature cytokines IL-4, IL-5 and IL-13 from cells of both the innate and adaptive immune systems. A number of well-recognized biomarkers have been linked to mechanisms involved in type 2 airway inflammation, including fractional exhaled nitric oxide, serum IgE, periostin, and blood and sputum eosinophils. These type 2 cytokines are targets for pharmaceutical intervention, and a number of therapeutic options are under clinical investigation for the management of patients with uncontrolled severe asthma. Anticipating and understanding the heterogeneity of asthma and subsequent improved characterization of different phenotypes and endotypes must guide the selection of treatment to meet individual patients' needs.

Related Papers

• Lebrikizumab reduces serum periostin in asthma patients with elevated baseline periostin(2012)
• → The Extent of Serum Periostin Reduction in Asthma Patients Treated with Lebrikizumab Is Related to Baseline Periostin Levels: A Pooled Analysis of Phase II Studies(2016)
• Periostin and Ischemic Heart Disease(2009)
• → EBC periostin concentration in children with mild-to moderate asthma(2019)
• → Establishment of a novel ELISA system for measuring periostin independently of formation of the IgA complex(2022)